Home Company Technology Alliances News Contact
BioSeek Drug Discovery

 

Welcome to Asterand!

We would like to welcome BioSeek customers, partners and employees to Asterand. This highly complementary acquisition will bring a broad array of products and services to all of our drug discovery clients.

BioSeek's BioMap® Systems will bring a unique and scalable platform to Asterand's product and service line. We are looking forward to bringing these two highly creative and quality-driven teams together to expand and grow the business!

BioSeek, Inc. is now BioSeek LLC,
a wholly-owned subsidiary of Asterand plc


To find out more about Asterand click here

News & Events

April 30, 2012
Final Results Statement

April 30, 2012
2011 Annual Report and Accounts

March 28, 2012
Asterand's Subsidiary BioSeek Extends Collaboration with Merck Serono

March 12, 2012
BioMAP® Profiling Provides Insights into Toxicity of Nanomaterials, Failed Drugs and Environmental Chemicals

March 6, 2012
Update on Formal Sale Process

Feburary 2012
EPA Expands Innovative Compound-Testing Collaboration With BioSeek

January, 2012
Asterand Subsidiary BioSeek and US EPA Expand ToxCastTM Collaboration

November 30, 2011
Asterand's Subsidiary BioSeek Achieves A Research Milestone In Drug Discovery Collaboration With Ono

June 8, 2011
Asterand Introduces New Human 3D Model for Diabetes Research

May 17, 2011
Interim Management Statement

May 4, 2011
Replay the Asterand plc 2010 Final Results Announcement Webcast

April 28, 2011
Asterand Releases 2010 Annual Report and Accounts

April 28, 2011
Asterand's Final Results Statement

April 28, 2011
Asterand Announces New Financing Arrangements

March 31, 2011
Asterand Awarded Key Patents on the BioMAP® Technology

March 29, 2011
Asterand and 5AM Solutions Enter a Preferred Partnership Agreement

March 3, 2011
Asterand Receives French Research Tax Credit Accreditation


BioMAP® Systems are integrated cell systems that generate a unique signature of human biological response for prediction of mechanisms and therapeutic efficacy. More...